Beware -- the use of MAO inhibitors is increasing again.
The use of monoamineoxidase inhibitors in the treatment of depression is increasing again in Australia. This paper outlines changes in prescribing, the problems associated with monoamineoxidase (MAO) inhibitors and how they relate to the practice of anaesthesia.
D000769:Anesthesia, Inhalation; D000777:Anesthetics / Q000009:adverse effects; D003863:Depression / Q000188:drug therapy*; D004347:Drug Interactions; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D008614:Meperidine / Q000009:adverse effects / Q000494:pharmacology; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D009020:Morphine / Q000009:adverse effects; D010423:Pentazocine / Q000009:adverse effects; D013390:Succinylcholine / Q000009:adverse effects; D013874:Thiopental / Q000009:adverse effects; D014662:Vasoconstrictor Agents / Q000009:adverse effects
D000777:Anesthetics; D008996:Monoamine Oxidase Inhibitors; D014662:Vasoconstrictor Agents; D009020:Morphine; D008614:Meperidine; D013390:Succinylcholine; D013874:Thiopental; D010423:Pentazocine